What is Tridek-One?
Founded in 2018, Tridek-One Therapeutics operates as a private biotechnology company dedicated to pioneering first-in-class CD31 checkpoint agonists. Its core strategy revolves around a platform-based methodology for creating bispecific antibodies designed to selectively target and neutralize pathogenic immune cells, thereby re-establishing immune homeostasis. The company's research and development efforts are concentrated on advancing its pipeline of immune modulating therapies, positioning it as a key player in the competitive landscape of autoimmune disease treatment. Tridek-One's commitment to scientific innovation is supported by a seasoned management team and substantial financial backing from prominent European investors.
How much funding has Tridek-One raised?
Tridek-One has raised a total of $16M across 1 funding round:
Unspecified
$16M
Unspecified (2022): $16M with participation from AdBio partners, Bpifrance, and Bioqube Ventures
Key Investors in Tridek-One
AdBio partners
AdBio partners is an investor participating in the funding round, likely focusing on early-stage biotechnology ventures.
Bpifrance
Bpifrance is a French public investment bank that finances companies at every stage of development, supporting innovation, international expansion, and export activities for startups, SMEs, and mid-cap companies.
Bioqube Ventures
Bioqube Ventures is a global life sciences investment firm that invests in companies developing first- or best-in-class therapeutics to address significant unmet medical needs, supporting them from inception through early clinical milestones.
What's next for Tridek-One?
With the recent infusion of major strategic investment, Tridek-One is poised to accelerate its research and development initiatives. The enterprise-level funding suggests a transition towards scaling operations and potentially advancing its bispecific antibody candidates through critical preclinical and early clinical stages. This capital injection will likely bolster the company's capacity for further scientific exploration, team expansion, and the strategic pursuit of regulatory milestones. The focus remains on leveraging its unique platform to address unmet needs in autoimmune disease therapy, aiming for significant therapeutic breakthroughs.
See full Tridek-One company page
